PLCE1-AS2: A potential drug target and biomarker for treatizing various diseases

Target Name: PLCE1-AS2

NCBI ID: G101927049

PLCE1-AS2

Other Name(s): PLCE1 antisense RNA 2, transcript variant 1 | PLCE1 antisense RNA 2

PLCE1-AS2: A potential drug target and biomarker for treatizing various diseases

PLCE1-AS2, a non-coding RNA molecule, has been identified as a potential drug target and biomarker for treating various diseases.PLCE1-AS2 has been shown to play a critical role in multiple biological processes, including cell signaling, DNA replication, and cellular stress response. Its expression has also been linked to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, targeting PLCE1-AS2 may provide new insights into the underlying mechanisms of these diseases and may lead to the development of new treatments.

Disease-related changes in PLCE1-AS2 expression

PLCE1-AS2 is involved in various cellular processes that are critical for maintaining cellular health and homeostasis. Mutations in PLCE1-AS2 have been observed in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. These mutations have been associated with altered cellular signaling pathways and disruptive cellular processes that can lead to the development of these diseases.

PLCE1-AS2 in cancer

PLCE1-AS2 has been shown to play a critical role in the development and progression of cancer. Many studies have shown that increased PLCE1-AS2 expression is associated with poor prognosis in cancer patients.PLCE1-AS2 has also been shown to promote the growth and survival of cancer cells, making it a potential drug target for cancer treatment.

PLCE1-AS2 in neurodegenerative diseases

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and progressive cognitive decline.PLCE1-AS2 has been shown to be involved in the development and progression of these diseases. Studies have shown that decreased PLCE1-AS2 expression is associated with the development of neurodegenerative diseases. Therefore, targeting PLCE1-AS2 may provide new insights into the underlying mechanisms of these diseases and may lead to the development of new treatments.

PLCE1-AS2 in autoimmune disorders

Autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis, are characterized by the immune system attacking the body's own tissues.PLCE1-AS2 has been shown to be involved in the development and progression of these disorders. Studies have shown that decreased PLCE1-AS2 expression is associated with the development of autoimmune disorders. Therefore, targeting PLCE1-AS2 may provide new insights into the underlying mechanisms of these disorders and may lead to the development of new treatments.

Targeting PLCE1-AS2

PLCE1-AS2 can be a potential drug target for treating various diseases due to its critical role in multiple cellular processes. Several approaches have been proposed to target PLCE1-AS2, including small molecule inhibitors, RNA-based therapeutics, and protein-based therapeutics.

Small molecule inhibitors

Small molecule inhibitors have been shown to be effective in targeting PLCE1-AS2.One such inhibitor, NXJ-2140, has been shown to inhibit PLCE1-AS2 expression and decrease the activity of the PLCE1-AS2-PLK2 signaling pathway.NXJ-2140 has also been shown to decrease the number of cancer cell colonies and improve the growth inhibition of cancer cells.

RNA-based therapeutics

RNA-based therapeutics have also been shown to be effective in targeting PLCE1-AS2.One such approach is using RNA interference (RNAi) to knock down PLCE1-AS2 expression in cancer cells.RNAi has been shown to be effective in reducing the amount of PLCE1-AS2 protein produced in cancer cells and suppressing its

Protein Name: PLCE1 Antisense RNA 2

The "PLCE1-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLCE1-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets